版权说明 操作指南
首页 > 成果 > 详情

The Progress of Small Molecule Targeting BCR-ABL in the Treatment of Chronic Myeloid Leukemia

认领
导出
Link by DOI
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Zhang, Yuan;Wu, Xin;Sun, Xueyan;Yang, Jun;Liu, Chang;...
作者机构:
[Peng, Junmei Peng; Lei, Xiaoyong; Huang, Honglin; Yang, Jun; Zhang, Yuan; Wu, Xin; Sun, Xueyan; Tang, Guotao; Liu, Chang] Department of Pharmacy, School of Pharmacy, Hengyang Medical School, Institute of Pharmacy and Pharmacology, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang, Hunan, 421001, China
语种:
英文
关键词:
BCR-ABL protein;CML;T315I mutation;molecular docking;proteolysis-targeting chimeric;tyrosine kinase inhibitors
期刊:
MINI-REVIEWS IN MEDICINAL CHEMISTRY
ISSN:
1389-5575
年:
2024
卷:
24
期:
6
页码:
642-663
机构署名:
本校为第一机构
院系归属:
药学与生物科学学院
摘要:
Chronic myelogenous leukemia (CML) is a malignant myeloproliferative disease. According to the American Cancer Society's 2021 cancer data report, new cases of CML account for about 15% of all leukemias. CML is generally divided into three stages: chronic phase, accelerated phase, and blast phase. Nearly 90% of patients are diagnosed as a chronic phase. Allogeneic stem cell transplantation and chemotherapeutic drugs, such as interferon IFN-α were used as the earliest treatments for CML. However, they could generate obvious side effects, and sci...

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com